These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 20123551

  • 1. Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance.
    Maggio R, Aloisi G, Silvano E, Rossi M, Millan MJ.
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S2-7. PubMed ID: 20123551
    [Abstract] [Full Text] [Related]

  • 2. Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D1/D2/D3 receptors vs D2/D3 receptors only: parallel observations from co-transfected human and native cerebral receptors.
    Aloisi G, Silvano E, Rossi M, Millan MJ, Maggio R.
    Neuropharmacology; 2011 Dec; 60(2-3):439-45. PubMed ID: 21035472
    [Abstract] [Full Text] [Related]

  • 3. Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance.
    Maggio R, Millan MJ.
    Curr Opin Pharmacol; 2010 Feb; 10(1):100-7. PubMed ID: 19896900
    [Abstract] [Full Text] [Related]

  • 4. [The therapeutic plasma concentrations of antiparkinson dopamine agonists and their in vitro pharmacology at dopamine receptors].
    Tadori Y, Kobayashi H.
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2014 Nov; 34(5-6):127-32. PubMed ID: 25536763
    [Abstract] [Full Text] [Related]

  • 5. Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors.
    Seeman P, Ko F, Willeit M, McCormick P, Ginovart N.
    Synapse; 2005 Nov; 58(2):122-8. PubMed ID: 16088951
    [Abstract] [Full Text] [Related]

  • 6. The peripheral dopaminergic system: morphological analysis, functional and clinical applications.
    Amenta F, Ricci A, Tayebati SK, Zaccheo D.
    Ital J Anat Embryol; 2002 Nov; 107(3):145-67. PubMed ID: 12437142
    [Abstract] [Full Text] [Related]

  • 7. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease.
    Piercey MF.
    Clin Neuropharmacol; 1998 Nov; 21(3):141-51. PubMed ID: 9617505
    [Abstract] [Full Text] [Related]

  • 8. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ, Konitsiotis S, Chase TN.
    J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors.
    Perachon S, Schwartz JC, Sokoloff P.
    Eur J Pharmacol; 1999 Feb 05; 366(2-3):293-300. PubMed ID: 10082211
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.